Quantitative analysis for Oramed Pharmaceuticals Inc. (ORMP) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Buy (92.0) (grade A). 24 signals analyzed (21 differentiated alt-data).
ORMP stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $4.03 | $3.83 | $3.84 |
| 2026-05-11 | $5.01 | $4.23 | $4.62 |
| 2026-05-21 | $4.43 | $4.13 | $4.38 |
| 2026-06-03 | $3.77 | $3.60 | $3.65 |
| 2026-06-15 | $3.92 | $3.82 | $3.84 |
| 2026-06-26 | $5.11 | $4.52 | $4.67 |
| 2026-07-09 | $4.38 | $4.18 | $4.18 |
| 2026-07-21 | $4.22 | $4.01 | $4.02 |
| 2026-07-31 | $4.13 | $3.94 | $4.07 |
| 2026-08-12 | $4.47 | $4.23 | $4.27 |
| 2026-08-24 | $4.86 | $4.74 | $4.82 |
| 2026-09-03 | $5.11 | $4.81 | $4.93 |
How Oramed Pharmaceuticals Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| IFRX | InflaRx N.V. | $176M | 38.0 |
| UNCY | Unicycive Therapeutics, Inc. | $166M | — |
| IMDX | Insight Molecular Diagnostics Inc. | $166M | — |
| IMRX | Immuneering Corporation | $182M | 36.0 |
View all Health Care stocks by valuation and signals →
Oramed Pharmaceuticals Inc. (ORMP) scores Strong Buy (92.0), and the composite conceals a 69-point disagreement between its dimensions. It is strongest on technicals at 89 and analyst consensus at 64, and weakest on competitive moat at 20. A stock can carry technicals that high while competitive moat sits at 20; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| technicals | 89 |
| analyst consensus | 64 |
| competitive moat | 20 |
StoQuant analyzes 24 signals (21 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Oramed Pharmaceuticals Inc. (ORMP): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/ORMP"><img src="https://stoquant.com/badge/ORMP.svg" alt="Oramed Pharmaceuticals Inc. (ORMP) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.